Member Info for Zoom0001

No need to thank me.

It's where everyone buys their first sofa on finance over 48 months at 49.9% APR as the deals are too good to miss.

There it is. RNS in the next couple of months nailed on.

17-May-22 09:46:09 108.89 911 Sell* 991.99

Well today’s certainly gone a long way to demonstrate they’re not sitting on their backsides doing nothing. They’ve had plenty of bad luck with AVACTA and DHSC. Let’s hope this is the turning point. I feel a lot more confident today than I did yesterday.

Totally agree. Just demonstrates what’s going on in the background.

We continue to make commercial progress in other areas and look forward to updating the market in due course.”

Let’s have DHSC payment and Vatic approval in short order. Imagine the effect on the price if everything falls in to place with these left field contracts dropping in.

Not bad..

https://www.londonstockexchange.com/news-article/ABDX/significant-contract-to-manufacture-lfd-components/15454798

Abingdon's creating the fear through a complete and utter lack of tangible news. I doubt Pumpky's posts will make a jot of difference to peoples investment decisions.

Hopefully the start of a news-rich period.

Don’t think they have a user friendly saliva test approved from anywhere, including the US.

This articles from the start of the pandemic. Maybe not so relevant now however Vatic certainly have some USP’s.

https://premierconsulting.com/resources/blog/emergency-use-authorizations-what-is-an-eua-and-does-your-product-qualify/#What-timelines-should-you-expect-for-the-review-process

I came across this.

What timelines should you expect for the review process?

In a critical ongoing or imminent situation, the FDA aims to review EUAs within hours or days. For instance, the FDA issued EUAs for COVID-19 diagnostic tests to Roche, Thermo Fisher Scientific, and Abbott Laboratories within 24 hours of their request submissions.

It’s about time Abingdon inject some optimism into the market. Appreciate certain aspects are out their hands but they must have something positive to share. I think there’s potential here but sentiments been completely flattened.

Bigjock, the IPO was December 2020. A bit awkward?

What exactly were you expecting? The price will
with the launch and approvals.

They are approved and will launch in May for professional use in Europe. EUA in the USA will come when it comes..hopefully soon.

According to the last presentation the US sites will be used to extend the phase one study, so they could potentially include dose escalation and expansion.

I’m not feeling the worked buy theory. I think it’s a case of investors expecting to have heard something today which is probably unrealistic.